Objective:

The objective of this study is to evaluate the effects of Sefacon™ on S. Neurona or S. Neospora infected equine. The scope of the evaluation is limited to equine that are diagnosed for EPM by a veterinarian or scientist using the Modified Mayhew Exam, and confirmed by WB (Western Blot) or IFA (Immunologic Fluorescent Antibody) analysis.

Location:

Headquarters of Animal Protection Coalition Inc., Frankfort, Indiana.  Research conducted by: 

Anthony R. Caldwell - sefacon@apcnaturalresearch.com
Kelsey Cook - kelsey@ihrmain.com
 

Dosage:

For the purposes of this evaluation we will use the serving standard of 20 mL oral paste twice daily for four days and 20 mL oral paste once daily for the following six days, for a total of fourteen servings.

Phase I Objective:

The objective of Phase I of this study is to evaluate the risks on equine of the supplement hereafter referred to as Sefacon™.  The scope of the evaluation is limited to equine that are in reasonably good health with no obvious deficits.  

Phase II Objective:

The objective of Phase II of this study is to evaluate the effect of the supplement Sefacon™, on equine diagnosed positive for EPM under the guidelines set forth in EPM Protocol Objective.  The scope of the evaluation will be limited to 5 EPM positive equine.

Phase III Objective:

The objective for Phase III of this study is to expand the research group to 20 EPM equine that comply with the guidelines set forth in EPM Protocol Objective.

Phase IV Objective:

For a period of two years post ingestion, monitor all horses given Sefacon™ to establish antibody levels, potential T-cell activity and establish potential re-infection rates if any.